Evidence map›Paper›PMID 32071730›Full record

ArticleJournal of pharmaceutical health care and sciences2020

Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study.

Motoyasu Miyazaki, Koichi Matsuo, Masanobu Uchiyama, Yoshihiko Nakamura, Yuya Sakamoto, Momoko Misaki, Kaoko Tokura, Shiro Jimi, Keisuke Okamura, Sen Adachi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of pharmaceutical health care and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Motoyasu Miyazaki1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Koichi Matsuo1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Masanobu Uchiyama1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Yoshihiko Nakamura2Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan; 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan.
Yuya Sakamoto1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Momoko Misaki1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Kaoko Tokura1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Shiro Jimi3Central Laboratory for Pathology and Morphology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan; 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan.
Keisuke Okamura4Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Sen Adachi4Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Tomohiko Yamamoto4Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Kazuyuki Shirai4Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Hidenori Urata4Department of Cardiovascular Diseases, Fukuoka University Chikushi Hospital, Fukuoka, Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Osamu Imakyure1Department of Pharmacy, Fukuoka University Chikushi Hospital, Fukuoka Japan; 1-1-1, Zokumyoin, Chikushino-shi, Fukuoka, 818-8502 Japan.
Fukuoka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInappropriate dosing of direct oral anticoagulants (DOACs) has been associated with clinical safety and efficacy; however, little is known about clinical data associated with an inappropriate DOAC dosing in Japan. In addition, there is no report in which the appropriateness of DOAC dosing between prescription for inpatients and for outpatients was examined. In this study, we aimed to investigate the prevalence and factors associated in the inappropriate dosing of DOACs in patients with atrial fibrillation (AF).

methodsThe retrospective cohort study was conducted at a single Japanese university hospital. Both inpatients and outpatients, who were diagnosed with AF and for whom treatment with either dabigatran, rivaroxaban, apixaban, or edoxaban was initiated between April 1, 2014 and March 31, 2018, were enrolled in the study. Appropriateness of DOAC dosing was assessed according to the manufacturer's labeling recommendations (dose reduction criteria) of each DOAC. Inappropriate reduced dose, namely, underdosing, was defined as prescription of a reduced dose of DOAC despite the patient not meeting the dose reduction criteria. Inappropriate standard dose, namely, overdosing, was defined as prescription of a standard dose of DOAC despite the patient meeting the dose reduction criteria. Inappropriate DOAC dosing was defined as a deviation of the recommended dose (both underdosing and overdosing).

resultsA total of 316 patients (dabigatran, 28; rivaroxaban, 107; apixaban, 116; and edoxaban, 65) were included, with a median (interquartile range) age of 75 (66-81) years and 62.3% male. DOACs were prescribed at an appropriate standard dose in 39.2% of patients, an appropriate reduced dose in 36.7%, an inappropriate standard dose in 2.5%, and an inappropriate reduced dose in 19.3%. Multivariate analysis revealed that the inappropriate dosing of DOACs was significantly associated with prescriptions for outpatients (vs. inpatients; odds ratio [OR] 2.87, 95% confidence interval [CI] 1.53-5.62,

conclusionsOur results demonstrated that the inappropriate dosing of DOACs occurred in approximately 20% of AF patients, and was more frequent in outpatients (vs. inpatients) and in those with a higher risk of bleeding. It is recommended that pharmacists play a greater role in assisting in the prescription process to help physicians make better decisions.

Indexed as

Direct oral anticoagulantInappropriate doseOutpatientPrescription

Identifiers

PMID32071730
PMCPMC7014592
OpenAlexW3012047666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.